Investors in NovoCure (NASDAQ:NVCR) Have Seen Notable Returns of 97% Over the Past Year

Simply Wall StJan 8 07:49 ET

SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?

Seeking AlphaJan 5 17:32 ET

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

NovocureJan 3 00:00 ET

Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46

Moomoo NewsJan 2 07:32 ET · Ratings

Novocure Price Target Raised to $46 From $34 at Evercore ISI

TipRanksJan 2 06:45 ET

Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025

ReutersDec 17, 2024 06:03 ET